Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

High historical growth rate, a proven business model and significant capacity for acquisitions creates good growth opportunities

A proven high historical growth rate, a proven business model, significant capacity for acquisitions and a more focused Volati creates a base for good growth opportunities going forward. This was concluded by Volati's management at the company's capital market’s day on Thursday. All presentations can be accessed via the link below from 08.00 am CET today. The capital markets update is followed by a Q&A session for investors and analysts on 22 March 2021 at 14.00 CET. Volati's Chairman of the Board Patrik Wahlén initially noted that a lot is happening within Volati: A distribution of

Lagercrantz prepares for continued expansion

Lagercrantz Group’s Board of Directors has today decided to approve the Management’s proposal for continued expansion. This means that the strategic direction and the financial goals are clarified, a reorganisation of the divisions and an increased focus on sustainability.Lagercrantz’s business concept has been successful over many years and represents a strong platform for future expansion. During the past 10 years, the share has generated a return of 30 percent per year including dividends. The expansion has been financed by cash flows from the operations and has been characterised by

Parkhuset – the innovation project with only half the climate impact

In a traditional new construction project, about 450 kg of CO[2]/sqm is currently emitted. Fabege is now starting to design Parkhuset in Solna Business Park, which is expected to achieve emissions of 225 CO[2]/sqm – this is only half the climate impact compared to a traditional new construction project.In order to achieve a 50% reduction in the climate impact, building parts from a demolition project in Solna Business Park will be reused, for example. Together with RISE, NCC and Codesign, an investigation has been carried out to ensure that parts from the concrete framework can be reused

Skanska divests office project in Copenhagen, Denmark, for DKK 917M, about SEK 1.2 billion

Skanska has divested an office building, in Copenhagen, Denmark, for DKK 917M, about SEK 1.2 billion. The buyer is Aviva Investors acting on behalf of one of its clients. The transaction will be recorded by Skanska Commercial Development Nordic in the first quarter 2021. The transfer of the property will take place April 7, 2021.The multitenant office project “CPH Highline” covers approximately 17,000 square meters offices and 167 parking lots. It has a very sustainable profile, with innovative solutions and will be DGNB gold certificated. The project was completed in December 2020 and is

SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been initiated following completion of the initial open label part of study. The second part is a randomized double-blind placebo-controlled study in 56 Covid-19 patients at clinical sites at Universidade Federal de Minas, Belo Horizonte, Brazil.The initial open label part of the study was conducted in 6 patients referred to hospital with Covid-19 induced pulmonary insufficiency, defined as a need

Aker ASA: Reporting of transactions made by persons discharging managerial responsibilities in Aker ASA’s shares

As fulfilment of existing rights under the 2020 bonus program for employees in Aker ASA ("Aker"), the following persons discharging managerial responsibilities in Aker have received bonus shares. The shares have a lock-in period of three years. Upon allocation, the value of the shares was set to NOK 552.48, which corresponds to the three-day average, volume-weighted price of Aker's share starting Monday 15 March 2021, to which a 20 per cent discount was applied. The bonus shares in Aker were distributed as follows: · Svein Oskar Stoknes, Chief Financial Officer, has received 1,

Size matters when it comes to atomic properties

A study from Chalmers University of Technology, Sweden, has yielded new answers to fundamental questions about the relationship between the size of an atom and its other properties, such as electronegativity and energy. The results pave the way for advances in future material development. For the first time, it is now possible under certain conditions to devise exact equations for such relationships.“Knowledge of the size of atoms and their properties is vital for explaining chemical reactivity, structure and the properties of molecules and materials of all kinds. This is

Kungsleden in major initiative in Västerås

Collaborative project approved for FinnslättenThe collaborative project based on ideas from “Vision Finnslätten” has now been approved by the Building Committee in Västerås. Kungsleden, in cooperation with ABB, commenced the preparatory work on Vision Finnslätten in 2018 and activities are fully under way to develop a train stop, an international school and a campus area, among other features.   In 2018, Kungsleden initiated a dialogue with its largest tenant at Finnslätten, ABB, on the development of the area. The ideas were discussed further with the City of Västerås, which

Pexip – increase of share capital following exercise of employee share options, and limited share sale by primary insiders

Oslo, 18 March 2021: Following vesting and exercise of previously issued employee options, the Board of Directors of Pexip Holding ASA ("Pexip" or the "Company", Oslo Børs ticker "PEXIP") has resolved, based on authorisation granted by the Company's general meeting held on 20 March 2020, to issue 2,253,896 new shares for an aggregate subscription price of NOK 72,320,810. The shares have been subscribed for by various employee option holders. The Company has also in cooperation with ABG Sundal Collier ASA, Carnegie AS and Pareto Securities AS (“the IPO syndicate”) facilitated a

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the "Company") on 17 March 2021 (the "AGM") where election of members to the board of directors was according to the nomination committee’s proposal. At the same AGM of the Company the board of directors was authorized to extend the Company’s restricted stock unit ("RSU") program and to issue RSUs to the board members. The RSUs are non-transferable and each RSU gives the right and obligation to acquire one share in the Company at a price of NOK 0.10 per share (corresponding to the nominal value of the shares) subject to

Embracer Group successfully completed a directed issue of 36,000,000 new B shares raising proceeds of roughly SEK 7.6 billion (approximately USD 890 million)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE INFORMATION: Embracer Group AB (the "Company" or “Embracer Group”) has, as announced in its press release on March 17, 2021, carried out an issue of 36,000,000 new Class B shares directed to institutional investors, resolved upon by the Board of

Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer

Oslo, Norway, 17 March 2021 Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun as Chief Executive Officer (CEO). He will take up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland. Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialisation experience with innovative oncology products and deep knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche (“Roche”). During his career at Roche, Mr Braun led the Lifecycle Management

Reviewing Notice to Annual General Meeting in Bioservo Technologies AB (publ)

The shareholders of Bioservo Technologies AB (publ), reg. no. 556650-7264 (”Company”), are hereby summoned to the annual general meeting on Monday 19 April 2021 at 4.00 p.m.,  Torshamnsgatan 35, Kista.With regards to the risks related to the spread of the Coronavirus (COVID-19), Bioservo has decided to take the following precautionary steps at the Annual General Meeting:•    No food or drink will be served.•    Participation by both Board of Directors and Management will be restricted.•    The duration of the General Meeting will be reduced, but without infringing on the rights of

Notice of extraordinary general meeting in Ascelia Pharma

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.   The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797 (“Ascelia Pharma”), are hereby invited to the extraordinary general meeting to be held on Tuesday 13 April 2021.In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has decided that the meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means

The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH

· Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in haemoglobin levels and showed improvements in key clinical outcomes · Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the EMA STOCKHOLM, Sweden and WALTHAM, Mass, USA  - Swedish Orphan Biovitrum AB (publ) (Sobi™)  (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (

Ascelia Pharma has carried out a directed new share issue raising SEK 200 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has successfully carried out a directed new share issue of 5,000,000 ordinary

BioGaia Invest (BGI) – a new subsidiary focusing on innovative investments to support the growth of BioGaia

As part of BioGaia AB’s ambition to grow and develop as an innovative life science company, a separate entity, BioGaia Invest (BGI), has been established. The focus of BGI will be to identify and invest in smaller companies focusing on ground-breaking technologies, services and products that will support the growth of BioGaia.To fuel continued strong growth and to stay in the forefront of research and innovation, BioGaia AB has created BioGaia Invest (BGI). A total of SEK150 million has been allocated to BGI to enable investments between SEK 5 to 15 million in exciting new companies

Addtech acquires ESi Controls Ltd

Addtech Power Solutions, a business area in the Addtech Group, has today signed an agreement to acquire 100% of the shares outstanding in ESi Controls Ltd. ESi (Energy Saving Innovative) Controls is a UK based company designing and delivering energy efficient electronic controls for heating and smart building applications. ESi Controls Ltd has a turnover of approximately GBP 8 million and have 15 employees. ESi will very effectively complement and strengthen Addtech's sustainability initiatives with its focus on providing bespoke energy efficient controls for major National and

Citycon Oyj: Flagging notification in accordance with Chapter 9 Section 10 of the Finnish Securities Markets Act

Citycon Oyj   Stock Exchange Release   17 March 2021 at 20:45 hrsCitycon Oyj has received on 17 March 2021 the following notification pursuant to Chapter 9, Section 5 of the Finnish Securities Market Act from CPP Investment Board European Holdings S.à r.l.:n (”CPPIBE”) according to which their total holding of shares of Citycon Oyj has decreased below ten (10) percent on 17 March 2021.As a result of the disposal, the Governance Agreement entered into between CPPIBE and Gazit-Globe Ltd. on 12 May 2014, as disclosed by Citycon Oyj through stock exchange releases on 13 May 2014 and 17 March

How to succeed with subscriptions in consumer goods: Lessons from the Best-in-class companies

Simon-Kucher & Partners and Babson College analyzed factors of success with subscriptions in the consumer goods sector.[Boston, MA] March 17, 2021 – In Spring 2020, the COVID-19 pandemic forced companies into a world of uncertainty. Consumers shifted to online shopping in record numbers, and the internet became the platform of choice to buy anything and everything. The boom in online shopping amplified customer interest in subscriptions across various consumer markets such as fashion, beauty, pet care, and childcare, with an already well-established reputation in digital and news media

Prime Minister backs growth of UK bioscience industries

PRIME Minister Boris Johnson today (Wednesday) identified bioscience as one of the UK’s growth areas for the future. Speaking in the House of Commons at Prime Minister’s Questions, Mr Johnson outlined a bright future for bioscience industries in the UK. He was responding to a question from Barrow and Furness MP Simon Fell relating to the recent announcement by GSK that it looks set to close its factory in Ulverston, Cumbria. GSK’s announcement comes at a time when a different company, Lakes BioScience has been granted planning permission to start work on a £350m biomanufacturing

Embracer Group announces intention to carry out a directed share issue of B shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE INFORMATION: Embracer Group AB (the "Company" or “Embracer Group”) hereby announces its intention to carry out a directed share issue of approximately 32 million Class B shares, which is intended to be resolved upon by the Board of Directors based on

Ascelia Pharma intends to carry out a directed new share issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has mandated Danske Bank and Pareto Securities (the "Bookrunners”) to evaluate

There are no items matching the current filter
There are no more items matching the current filter
Back to top